Research letterUstekinumab does not increase tuberculosis risk: Results from a national database in South Korea
References (5)
- et al.
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
J Am Acad Dermatol
(2019) - et al.
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection
Br J Dermatol
(2012)
There are more references available in the full text version of this article.
Cited by (0)
Drs Lee and Jo contributed equally to this article.
Funding sources: None.
Conflicts of interest: None disclosed.
IRB approval status: Reviewed and approved by the SMG-SNU Boramae Medical Center IRB, Seoul, South Korea (07-2019-21/082).
Reprints not available from the authors.
© 2019 by the American Academy of Dermatology, Inc.